1.68
-0.63 (-27.27%)
| Previous Close | 2.31 |
| Open | 2.34 |
| Volume | 617,713 |
| Avg. Volume (3M) | 142,215 |
| Market Cap | 2,910,008 |
| Price / Sales | 0.580 |
| Price / Book | 1.11 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2026 |
| Operating Margin (TTM) | -330.18% |
| Diluted EPS (TTM) | -2.80 |
| Current Ratio (MRQ) | 2.55 |
| Operating Cash Flow (TTM) | -24.68 M |
| Levered Free Cash Flow (TTM) | -16.53 M |
| Return on Assets (TTM) | -915.19% |
| Return on Equity (TTM) | -78,814.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | GeoVax Labs, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 7.72% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fiduciary Alliance Llc | 31 Dec 2025 | 1,400 |
| Moneta Group Investment Advisors Llc | 31 Dec 2025 | 800 |
| 52 Weeks Range | ||
| Median | 6.00 (257.14%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 21 Jan 2026 | 6.00 (257.14%) | Buy | 2.98 |
| 19 Nov 2025 | 6.00 (257.14%) | Buy | 10.38 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |